There were 0.5% of participants who died because of serious adverse reactions.
This was 5 out of 998 participants.
> • 0.6% of participants getting MEDI4736 with tremelimumab died
because of a serious adverse reaction. This was 2 out of 340 participants.
> • 0.6% of participants getting MEDI4736 alone died because of a serious
adverse reaction. This was 2 out of 345 participants.
> • 0.3% of participants getting chemotherapy died because of a serious
adverse reaction. This was 1 out of 313 participants.
What adverse reactions happened during this study?
The most common adverse reactions were fatigue and nausea.
The table below shows the adverse reactions that happened in 10.0% or more
of participants during the study. There were other adverse reactions, but these
happened in fewer participants.
Most common adverse reactions
MEDI4736 with MEDI4736
Chemotherapy
tremelimumab alone
Adverse reaction (out of 313
(out of 340 (out of 345
participants)
participants) participants)
Itching 22.9% (78) 10.4% (36) 3.5% (11)
Diarrhea 21.2% (72) 6.7% (23) 10.5% (33)
Fatigue 14.4% (49) 11.9% (41) 27.2% (85)
Decreased appetite 7.4% (25) 6.7% (23) 19.2% (60)
Nausea 4.7% (16) 7.8% (27) 40.9% (128)
Anemia 2.1% (7) 1.7% (6) 41.9% (131)
14 | Clinical Study Results